Patent US2203871A successfully refreshed from Google Patents.
Patent US4777244A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4777244A Expired / Lapsed US ⏱️ 0.0 years remaining

Crosslinked hemoglobin of extended shelf life and high oxygen transport capacity and process of preparing same

Assignee: Biotest AG
•
Filing: 1987-05-08
•
Granted: 1988-10-11
•
Expires: 2007-05-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Crosslinked hemoglobin preparations of extended shelf life and high oxygen transport capacity can be made by reducing a hemoglobin solution with an oxygen consuming reducing agent down to an oxygen partial pressure of 0 mbar, then adding an effector, crosslinking with a dialdehyde, reducing with a carbonyl-group-specific reducing agent, circulating through an ultrafilter, and stabilizing the product by adding a reducing agent thereto.

Inventors

  • 👤 Klaus Bonhard
  • 👤 Norbert Kothe

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 11:34
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/795; C07K14/805; A; A61; A61P; A61P7/00; A61P7/08; A61K; A61K38/00

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 155 words
In the preparation of a crosslinked hemoglobin of extended shelf life and high oxygen transport capacity wherein a stroma-free hemoglobin solution is treated with an effector and crosslinked with a dialdehyde having carbon chains of 3 to 8 carbon atoms, the improvement which comprises contacting a stroma-free, concentrated hemoglobin solution with so much of an ox/gen-consuming reducing agent that the O 2 partial pressure diminishes to substantiall 0 mbar, contacting the deoxygenated product thus obtained with a physiologically tolerable effector and then, at a pH between about 6 and 8, with the dialdehyde, reducing the crosslinked product so obtained with about 5 to 20 times the molar amount of a carbonyl-group-specific reducing agent, diluting the solution with water, ultrafiltering and recirculating the solution until the content of un-crosslinked hemoglobin amounts to no more than about 15%, the crosslinking being effected before or during the ultra-filtration, and adding a reducing agent thereby to stabilize the solution.
Claim 2
Dependent Claim 155 words
In the preparation of a crosslinked hemoglobin of extended shelf life and high oxygen transport capacity wherein a stroma-free hemoglobin solution is treated with an effector and crosslinked with a dialdehyde having carbon chains of 3 to 8 carbon atoms, the improvement which comprises contacting a stroma-free, concentrated hemoglobin solution with so much of an ox/gen-consuming reducing agent that the O 2 partial pressure diminishes to substantiall 0 mbar, contacting the deoxygenated product thus obtained with a physiologically tolerable effector and then, at a pH between about 6 and 8, with the dialdehyde, reducing the crosslinked product so obtained with about 5 to 20 times the molar amount of a carbonyl-group-specific reducing agent, diluting the solution with water, ultrafiltering and recirculating the solution until the content of un-crosslinked hemoglobin amounts to no more than about 15%, the crosslinking being effected before or during the ultra-filtration, and adding a reducing agent thereby to stabilize the solution.
Claim 3
Dependent Claim 15 words
The process according to claim 1, wherein the effector comprises pyridoxal phosphate or inositol hexaphosphate.
Claim 4
Dependent Claim 23 words
The process according to claim 1, wherein the oxygen-consuming reducing agent is ascorbic acid, reduced glutathion, reduced methylene blue or neutralized ascorbic acid.
Claim 5
Dependent Claim 16 words
The process according to claim 3, wherein the oxygen consuming reducing agent is neutralized ascorbic acid.
Claim 6
Dependent Claim 15 words
The process according to claim 1, wherein the carbonyl-group-specific reducing agent comprises NaBH 4 .
Claim 7
Dependent Claim 20 words
The crosslinked hemoglobin preparation of long shelf life and high oxygen transport capacity produced by the process of claim 1.

References Cited (Backward Citations)

US4061736A Cited
US4136093A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-10-11 1992-04-11 1992-10-11 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-10-11 1996-04-11 1996-10-11 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-10-11 2000-04-11 2000-10-11 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag